+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

United States Generic Drugs Market, By Therapeutic Application [Central Nervous System (CNS), Cardiovascular, Dermatology, Genitourinary (GU)/Harmonal Drugs, Respiratory, Anti-infective, Oncology & Others], Companies

  • ID: 4577461
  • Report
  • Region: United States
  • 120 Pages
  • Renub Research
1 of 4

FEATURED COMPANIES

  • Dr Reddy’s
  • Endo Pharmaceuticals
  • Lupin Limited
  • Mylan N.V.
  • Sandoz
  • Sun Pharma
  • MORE

United States Generic Drugs Market is projected to exceed USD 210 Billion by 2024. United States Generic Drugs Market is so huge that nearly 80% of dispensing prescriptions accounts generic drugs. According to FDA in the United States 9 out of 10 prescriptions filled are for generic drugs. Most of the physicians and hospitals are now prescribing generic drugs than that of the brand-name drugs. Generic Drugs are those drugs which have same active component as patent drugs in same outline & equal amounts. Generic drugs are also called as Off-Label drugs.

The prime reason for the growth of United States Generic Drugs Market can be attributed to its pricing, on an average generic (Off-Label) drug is around 40-60% cheaper than those of Branded Drugs. However, this price of generic drug further declines, when various generic drug companies target a single approved drug, then market competition results in prices 85% less than the branded drugs. Also, increasing number of drug patent expirations, government initiatives and rising prevalence of chronic diseases are some other factors which are expected to propel the growth of United States Generic Drugs Market in the near future.

The report titled “United States Generic Drugs Market, By Therapeutic Application [Central Nervous System (CNS), Cardiovascular, Dermatology, Genitourinary (GU)/Harmonal Drugs, Respiratory, Anti-infective, Oncology & Others], Companies (Teva, Mylan N.V., Sandoz, Endo Pharmaceuticals, Lupin Limited, Dr Reddy’s, Sun Pharma, & Others)” provides a complete analysis of US Generic Drugs Market.

Therapeutic Application – Oncology Generic Drug Market is likely to witness a Significant Growth during the Forecast Period

The report studies the market of the following Therapeutic Application segments: Central Nervous System (CNS), Cardiovascular, Dermatology, Genitourinary (GU) / Harmonal Drugs, Respiratory, Anti-infective, Oncology & Others. Central Nervous System (CNS), Cardiovascular, Respiratory and Oncology are some of the segments that will attract the attention of generic drugs market participants.

All companies in this report has been covered with following view points

  1. Company Strategy
  2. Sales

Companies Analysis

Teva, Mylan, Sandoz, Endo Pharmaceuticals, Lupin Limited, Dr Reddy’s, Sun Pharma are some of the top companies operating in the United States Generic Drug Market; which has been studied thoroughly in the report.

By Therapeutic Application:

  • Central Nervous System (CNS)
  • Cardiovascular
  • Dermatology
  • Genitourinary (GU)/Harmonal Drugs
  • Respiratory
  • Anti-infective
  • Oncology
  • Others

Key Companies Covered in the Report:

  • Teva
  • Mylan N.V.
  • Sandoz
  • Endo Pharmaceuticals
  • Lupin Limited
  • Dr Reddy’s
  • Sun Pharma
  • Others
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Dr Reddy’s
  • Endo Pharmaceuticals
  • Lupin Limited
  • Mylan N.V.
  • Sandoz
  • Sun Pharma
  • MORE

1. Executive Summary

2. United States Pharmaceutical Market
2.1 Branded Pharmaceutical Market
2.2 Generics Pharmaceutical Market

3. United States Generic Drugs Saving

4. Market Share – United States Pharmaceutical
4.1 Branded vs. Generics Drugs
4.2 Branded Generic vs. Unbranded Generic Drug
4.3 Volume Penetration – Generic vs. Branded Drugs
4.4 Therapeutic Application

5. United States Generic Drugs Market (2010 – 2024)
5.1 Branded Generic Drugs Market
5.2 Unbranded Generic Drugs Market

6. Therapeutic Application – United States Generic Drugs Market (2010 – 2024)
6.1 Central Nervous System (CNS)
6.2 Cardiovascular
6.3 Dermatology
6.4 Genitourinary / Hormonal Drugs
6.5 Respiratory
6.6 Anti-infective
6.7 Oncology
6.8 Others

7. Teva Pharmaceutical Industries Ltd - Company Analysis
7.1 Product Launch
7.1.1 Point No. 1
7.1.2 Point No. 2
7.1.3 Point No. 3
7.1.4 Point No. 4
7.1.5 Point No. 5
7.1.6 Point No. 6
7.2 Financial Insight

8. Mylan N.V. - Company Analysis
8.1 Product Launch
8.1.1 Point No. 1
8.1.2 Point No. 2
8.1.3 Point No. 3
8.1.4 Point No. 4
8.1.5 Point No. 5
8.1.6 Point No. 6
8.2 Financial Insight

9. Sandoz Inc. - Company Analysis
9.1 Product Launch
9.1.1 Point No. 1
9.1.2 Point No. 2
9.2 Financial Insight

10. Endo Pharmaceuticals - Company Analysis
10.1 Product Launch
10.1.1 Point No. 1
10.1.2 Point No. 2
10.1.3 Point No. 3
10.1.4 Point No. 4
10.2 Financial Insight

11. Lupin Limited - Company Analysis
11.1 Product Launch
11.1.1 Point No. 1
11.1.2 Point No. 2
11.1.3 Point No. 3
11.1.4 Point No. 4
11.1.5 Point No. 5
11.1.6 Point No. 6
11.1.7 Point No. 7
11.2 Financial Insight

12. Dr Reddy's - Company Analysis
12.1 Business Portfolio
12.1.1 Point No. 1
12.1.2 Point No. 2
12.1.3 Point No. 3
12.2 Financial Insight

13. Sun Pharmaceutical Industries Ltd. - Company Analysis
13.1 Product Launch
13.1.1 Point No. 1
13.1.2 Point No. 2
13.1.3 Point No. 3
13.1.4 Point No. 4
13.2 Financial Insight

14. Others
14.1 Financial Insight

15. Growth Driver
15.1 Rising Geriatric Population of United States
15.2 Generic Drugs Cost less than Brand Name Drugs
15.3 Rising Incidence of non-communicable Diseases

16. Challenges
16.1 Lack of Regulation & Information
16.2 Long Halt for Expiration of Patent Drug

List of Figures:
Figure 2-1: US Pharma Market (Billion US$), 2010 – 2017
Figure 2-2: Forecast for US Pharma Market (Billion US$), 2018 – 2024
Figure 2-3: US Branded Pharma Market (Billion US$), 2010 – 2017
Figure 2-4: Forecast for US Branded Pharma Market (Billion US$), 2018 – 2024
Figure 2-5: US Generics Pharma Market (Billion US$), 2010 – 2017
Figure 2-6: Forecast for US Generics Pharma Market (Billion US$), 2018 – 2024
Figure 3-1: Savings from Generics in (Billions US$), - 2016
Figure 3-2: US Generic Saving (Billion US$), 2010 – 2017
Figure 3-3: Forecast for US Generic Saving (Billion US$), 2018 – 2024
Figure 4-1: US Pharmaceutical Market Share (%), 2010 – 2017
Figure 4-2: Forecast for US Pharmaceutical Market Share (%), 2018 – 2024
Figure 4-3: Generic Drug Market Share (%), 2010 – 2017
Figure 4-4: Forecast for Generic Drug Market Share (%), 2018 – 2024
Figure 4-5: US Generic V.S. Branded Drug Volume Penetration (%), 2010 – 2017
Figure 4-6: Forecast for US Generic V.S. Branded Drug Volume Penetration (%), 2018 – 2024
Figure 4-7: US Generic Drugs - By Therapeutic Application Market Share (%), 2010 - 2017
Figure 4-8: Forecast for US Generic Drugs - By Therapeutic Application Market Share (%), 2018 - 2024
Figure 5-1: Branded Generic Drug Market (Billion US$), 2010 – 2017
Figure 5-2: Forecast for Branded Generic Drug Market (Billion US$), 2018 – 2024
Figure 5-3: Unbranded Generic Drug Market (Billion US$), 2010 – 2017
Figure 5-4: Forecast for Unbranded Generic Drug Market (Billion US$), 2018 – 2024
Figure 6-1: Central Nervous System Market (Billion US$), 2010 – 2017
Figure 6-2: Forecast for Central Nervous System Market (Billion US$), 2018 – 2024
Figure 6-3: U.S Incidence of cardiovascular disease by age and sex -2013
Figure 6-4: Cardiovascular Market (Billion US$), 2010 – 2017
Figure 6-5: Forecast for Cardiovascular Market (Billion US$), 2018 – 2024
Figure 6-6: Skin Diseases Prevalence in US – 2013
Figure 6-7: Dermatology Market (Million US$), 2010 – 2017
Figure 6-8: Forecast for Dermatology Market (Million US$), 2018 – 2024
Figure 6-9: Genitourinary/Hormonal Drugs Market (Billion US$), 2010 – 2017
Figure 6-10: Forecast for Genitourinary/Hormonal Drugs Market (Billion US$), 2018 – 2024
Figure 6-11: Respiratory Market (Billion US$), 2010 – 2017
Figure 6-12: Forecast for Respiratory Market (Billion US$), 2018 – 2024
Figure 6-13: Anti-infective Market (Billion US$), 2010 – 2017
Figure 6-14: Forecast for Anti-infective Market (Billion US$), 2018 – 2024
Figure 6-15: Oncology Market (Billion US$), 2010 – 2017
Figure 6-16: Forecast for Oncology Market (Billion US$), 2018 – 2024
Figure 6-17: Others Market (Billion US$), 2010 – 2017
Figure 6-18: Forecast for Others Market (Billion US$), 2018 – 2024
Figure 7-1: Teva – US Generic Drugs Market (Million US$), 2011 – 2017
Figure 7-2: Forecast for Teva – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 8-1: Mylan NV – US Generic Drugs Market (Million US$), 2011 – 2017
Figure 8-2: Forecast for Mylan NV – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 9-1: Sandoz – US Generic Drugs Market (Million US$), 2011 – 2017
Figure 9-2: Forecast for Sandoz – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 10-1: Endo Pharmaceuticals – US Generic Drugs Market (Million US$), 2012 – 2017
Figure 10-2: Forecast for Endo Pharmaceuticals – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 11-1: Lupin Limited – US Generic Drugs Market (Million US$), 2011 – 2017
Figure 11-2: Forecast for Lupin Limited – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 12-1: Dr Reddy’s – North America (US & Canada) Generic Drugs Market (Million US$), 2011 – 2017
Figure 12-2: Forecast for Dr Reddy’s – North America (US & Canada) Generic Drugs Market (Million US$), 2018 – 2024
Figure 13-1: Sun Pharma –US Generic Drugs Market (Million US$), 2011 – 2017
Figure 13-2: Forecast for Sun Pharma –US Generic Drugs Market (Million US$), 2018 – 2024
Figure 14-1: Others - US Generic Drugs Market (Million US$), 2011 – 2017
Figure 14-2: Forecast for Others –US Generic Drugs Market (Million US$), 2018 – 2024
Figure 15-1: United States - Rising Geriatric Population (Million), 2000, 2016 & 2060

List of Tables:
Table 3 1: Top 10 Generic Drugs Ranked by Savings in US - 2016
Table 3 2: Ten Major US State Generic Saving in - 2016
Table 6 1: The Full Burden of 24 Skin Disease categories

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Teva
  • Mylan N.V.
  • Sandoz
  • Endo Pharmaceuticals
  • Lupin Limited
  • Dr Reddy’s
  • Sun Pharma
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll